🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to researchers.

An International Challenge

Gonorrhoea infections are on the rise around the world, with figures suggesting in excess of 82 million instances per year. Especially elevated rates are reported in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the face of rising global incidence, the spread of superbugs and the extremely scarce available drugs at this time.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is employed against UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to see it through.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

As per data detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have expressed hope. Having a easy-to-administer therapy like this is hailed as a "critical tool" for managing the epidemic. This is considered essential to reduce the burden of the infection for people and to prevent the spread of untreatable gonorrhoea around the world.